Aptose Biosciences (APTO) shares were down almost 23% in recent Wednesday trading even as the company said it initiated a new phase 1/2 study for newly diagnosed acute myeloid leukemia patients.

The company said it started the Tuscany phase 1/2 study to evaluate the dosage of a drug cocktail that includes tuspetinib combined with azacitidine and venetoclax. The drug trio is being developed as a front line treatment for acute myeloid leukemia, Aptose said.

Aptose said it expects to enroll 18 to 24 subjects in the study by mid-late 2025 across 12 planned sites in the US.

Price: 0.28, Change: -0.08, Percent Change: -22.72